Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Agilent Completes BIOVECTRA Acquisition | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Agilent Completes BIOVECTRA Acquisition

Expands its portfolio of CDMO services, adds rapidly growing modalities and brings world-class capabilities to support gene editing.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Agilent Technologies Inc. has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.
 
All closing conditions are completed, including receipt of regulatory approvals. BIOVECTRA is now part of Agilent’s Diagnostics and Genomics Group.
 
“We are delighted to officially welcome the BIOVECTRA team to Agilent,” said Agilent President and CEO Padraig McDonnell. “This acquisition demonstrates our commitment to providing customers the most advanced capabilities to accelerate their therapeutics programs, including best-in-class cGMP pharmaceutical manufacturing.”
 
With the addition of BIOVECTRA, Agilent will expand its portfolio of CDMO services, add rapidly growing modalities, and bring world-class capabilities to support gene editing.
 
Both BIOVECTRA and Agilent are fully integrated CDMOs with facilities that follow current Good Manufacturing Practices (cGMP), a high standard for methods, facilities, and controls used in manufacturing, processing, and packaging of active pharmaceutical ingredients.

More Mergers & Acquisitions

Read Contract Pharma’s 2024 Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters